increased solubility = different PK profile? [Dissolution / BCS / IVIVC]

posted by nobody – 2017-06-08 19:43 (3300 d 12:25 ago) – Posting: # 17467
Views: 17,475

❝ O.k., I see I need to add some more information. The idea behind this question is to develop an oral formulation with a less drug load than the reference product but with the same bioavailability in order to decrease non-systemic adverse events.


If you claim less AEs, you will have to proof it. In my opinion. So: Clinical trials ahead, I guess.

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
137 visitors (0 registered, 137 guests [including 25 identified bots]).
Forum time: 08:09 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5